Iovance announces data showing durable responses with Lifileucel TIL cell therapy in advanced soft tissue sarcomas at ESMO 2026.
Iovance announces data showing durable responses with Lifileucel TIL cell therapy in advanced soft tissue sarcomas at ESMO 2026.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in